Aerolef

YM BioSciences Reports AeroLEF Randomized Phase IIb Trial Meets Primary Endpoint in Patients with Post-Surgical Pain

MISSISSAUGA, ON, May 02, 2007 /PRNewswire-FirstCall/ - YM BioSciences Inc. , an oncology company that identifies, develops and commercializes differentiated products for patients worldwide, today announced top-line results from its randomized, placebo-controlled Phase IIb trial of AeroLEF(TM) in o...

YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial

- Company Announces Lead Investigator for U.S. Trial - MISSISSAUGA, ON, July 11, 2007 /PRNewswire-FirstCall/ - YM BioSciences Inc. , an oncology company that identifies, develops and commercializes differentiated products for patients worldwide, today announced results of secondary endpoint data f...

YM BIOSCIENCES ANNOUNCES NIMOTUZUMAB PRESENTATIONS TO BE MADE AT THE 100TH ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH AND EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY

..., and was developed at the Center of Molecular Immunology. YM is developing aerolef for the treatment of moderate to severe acute pain. The product is differen...lly control the analgesia required for their differing intensities of pain. aerolef met all endpoints in a randomized Phase II trial and is currently being pre...

Aerolef in Biological Technology

YM BIOSCIENCES' SUBSIDIARY RESOLVES PROPOSED ARBITRATION WITH ONCOSCIENCE AG

..., and was developed at the Center of Molecular Immunology. YM is developing aerolef for the treatment of moderate to severe acute pain. The product is differen...lly control the analgesia required for their differing intensities of pain. aerolef met all endpoints in a randomized Phase II trial and is currently being pre...

YM BIOSCIENCES REPORTS DAIICHI-SANKYO ENROLLS FIRST PATIENTS IN PHASE II, FIRST-LINE LUNG CANCER TRIAL WITH NIMOTUZUMAB

..., and was developed at the Center of Molecular Immunology. YM is developing aerolef for the treatment of moderate to severe acute pain. The product is differen...lly control the analgesia required for their differing intensities of pain. aerolef met all endpoints in a randomized Phase II trial and is currently being pre...

NIMOTUZUMAB DEMONSTRATES EFFICACY IN RANDOMIZED HEAD & NECK CANCER STUDY WITHOUT THE TOXICITIES ASSOCIATED WITH OTHER EGFR DRUGS

..., and was developed at the Center of Molecular Immunology. YM is developing aerolef for the treatment of moderate to severe acute pain. The product is differen...lly control the analgesia required for their differing intensities of pain. aerolef met all endpoints in a randomized Phase II trial and is currently being pre...

YM BIOSCIENCES ANNOUNCES RESULTS OF RANDOMIZED NIMOTUZUMAB STUDY TO BE PRESENTED IN A POSTER AT ASCO ANNUAL MEETING

..., and was developed at the Center of Molecular Immunology. YM is developing aerolef for the treatment of moderate to severe acute pain. The product is differen...lly control the analgesia required for their differing intensities of pain. aerolef met all endpoints in a randomized Phase II trial and is currently being pre...

YM BIOSCIENCES REPORTS THIRD QUARTER 2009 OPERATIONAL AND FINANCIAL RESULTS

..., and was developed at the Center of Molecular Immunology. YM is developing aerolef for the treatment of moderate to severe acute pain. The product is differen...lly control the analgesia required for their differing intensities of pain. aerolef met all endpoints in a randomized Phase II trial and is currently being pre...

YM BIOSCIENCES ANNOUNCES FDA LIFTS CLINICAL HOLD ON AEROLEF(R) AND CLEARANCE OF A PHASE II CLINICAL TRIAL

... - Dr. Ali Raza To Lead Further Development Of aerolef As President Of aerolef Division - MISSISSAUGA, ON, June 19 /PRNewswire-...of the Phase II clinical development of AeroLEF. aerolef is being developed as a novel and effective approa...